首页> 外文期刊>European Journal of Cancer Supplements >7136 Randomized, placebo-controlled, phase 3 study of everolimus, a novel therapy for patients with metastatic renal cell carcinoma: subgroup analysis of patients progressing on prior bevacizumab therapy

【24h】

7136 Randomized, placebo-controlled, phase 3 study of everolimus, a novel therapy for patients with metastatic renal cell carcinoma: subgroup analysis of patients progressing on prior bevacizumab therapy

机译：7136依维莫司的一项随机，安慰剂对照，3期研究，这是一种转移性肾细胞癌患者的新疗法：对先前贝伐单抗治疗进展的患者进行亚组分析

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2009年第2期|共1页
作者
T.Hutson; S.Negrier; A.Kay;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. 7157 Subgroup analysis of French patients from RECORD-1: a randomized, placebo-controlled, phase III study of everolimus, a novel therapy for patients with metastatic renal cell carcinoma [J] . A.Ravaud, A.Kay, D.Lewohl European Journal of Cancer Supplements . 2009,第2期

机译：法国RECORD-1患者的7157亚组分析：依维莫司的一项随机，安慰剂对照的III期临床研究，依维莫司是一种治疗转移性肾细胞癌患者的新疗法
2. 7157 Subgroup analysis of French patients from RECORD-1: a randomized, placebo-controlled, phase III study of everolimus, a novel therapy for patients with metastatic renal cell carcinoma [J] . A.Ravaud, A.Kay, D.Lewohl European Journal of Cancer Supplements . 2009,第2期

机译：法国RECORD-1患者的7157亚组分析：依维莫司的一项随机，安慰剂对照的III期临床研究，依维莫司是一种治疗转移性肾细胞癌患者的新疗法
3. RECORD-2: phase II randomized study of everolimus and bevacizumab versus interferon alpha-2a and bevacizumab as first-line therapy in patients with metastatic renal cell carcinoma [J] . Ravaud A., Barrios C. H., Alekseev B., Annals of oncology: official journal of the European Society for Medical Oncology . 2015,第7期

机译：RECORD-2：依维莫司和贝伐单抗与干扰素α-2a和贝伐单抗作为转移性肾细胞癌患者的一线治疗的II期随机研究
4. When to Treat Metastatic Renal Cell Carcinoma Comorbidities, Systemic Therapy, and Active Surveillance in Metastatic Kidney Cancer [C] . Brian I. Rini Genitourinary Cancers Symposium . 2012

机译：何时治疗转移性肾细胞癌的组合，全身治疗，以及在转移性肾癌中的活跃监测
5. Methodological Approaches for Conducting Claims-Based Studies in Patients Diagnosed with Metastatic Renal Cell Carcinoma [D] . Chun, Danielle S. 2021

机译：用于诊断转移性肾细胞癌的患者的基于权利要求的基于权利要求的方法论方法
6. Randomized Phase 2 Study of Trebananib (AMG 386) with or without Continued Anti-Vascular Endothelial Growth Factor Therapy in Patients with Renal Cell Carcinoma Who Have Progressed on Bevacizumab Pazopanib Sorafenib or Sunitinib – Results of NCI/CTEP Protocol 9048 [O] . Thomas J Semrad, Susan Groshen, Chunqiao Luo, -1

机译：Trebananib（AMG 386）接受或不接受持续抗血管内皮生长因子治疗在贝伐单抗帕唑帕尼索拉非尼或舒尼替尼方面进展的肾细胞癌患者的随机2期随机研究– NCI / CTEP协议9048的结果
7. A phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor-targeted therapies [O] . McKay, R., De Velasco, G., Werner, L., 2016

机译：针对血管内皮生长因子靶向治疗进展的转移性肾细胞癌患者buparlisib和bevacizumab的1期研究

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

客服微信
服务号